Published in BJU Int on February 01, 2005
Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24
Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology (2005) 3.40
Clinical and demographic characteristics associated with prostate cancer progression in patients on active surveillance. J Urol (2012) 2.70
A prospective study measuring penile length in men treated with radical prostatectomy for prostate cancer. J Urol (2003) 2.59
Renal carcinoma with supradiaphragmatic tumor thrombus: avoiding sternotomy and cardiopulmonary bypass. Ann Thorac Surg (2010) 2.51
Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol (2010) 2.48
The learning curve of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. Eur Urol (2010) 2.39
Hyaluronic acid and HYAL-1 in prostate biopsy specimens: predictors of biochemical recurrence. J Urol (2009) 2.36
Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols. Eur Urol (2012) 2.28
ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol (2012) 2.19
"Complete transurethral resection of bladder tumor": are the guidelines being followed? Urology (2009) 2.16
Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol (2010) 2.13
Complications of intravesical therapy for urothelial cancer of the bladder. J Urol (2006) 1.99
A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol (2009) 1.97
Surgical margin status after robot assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. J Urol (2010) 1.86
Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer. Cancer (2013) 1.75
Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. BJU Int (2007) 1.72
HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer. Eur Urol (2009) 1.72
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol (2012) 1.66
Transurethral bladder tumor resection: intraoperative and postoperative complications in a residency setting. J Urol (2005) 1.66
Are patients with hematuria appropriately referred to Urology? A multi-institutional questionnaire based survey. Urol Oncol (2008) 1.64
Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol (2012) 1.63
Should we abandon the FISH test? Eur Urol (2007) 1.62
Clinical outcomes after telemedicine intensive care unit implementation. Crit Care Med (2012) 1.58
Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology (2007) 1.56
Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated? BJU Int (2004) 1.56
Modified Pfannenstiel approach for radical retropubic prostatectomy. Urology (2004) 1.55
Improving risk stratification in patients with prostate cancer managed by active surveillance: a nomogram predicting the risk of biopsy progression. BJU Int (2013) 1.54
Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation. Urology (2006) 1.49
Comparative validation of nomograms predicting clinically insignificant prostate cancer. Urology (2013) 1.49
Muscle-invasive urothelial carcinoma of the bladder. Urology (2007) 1.46
ICUD-EAU International Consultation on Bladder Cancer 2012: Urinary diversion. Eur Urol (2012) 1.42
Is adjuvant chemotherapy for bladder cancer safer in patients with an ileal conduit than a neobladder? BJU Int (2005) 1.40
Radical cystectomy for BCG failure: has the timing improved in recent years? BJU Int (2010) 1.40
It's not a radical prostatectomy, it's a total prostatectomy. Eur Urol (2008) 1.39
Do unto others--why I would want anesthesia for my prostate biopsy. Urology (2003) 1.38
Photodynamic diagnosis in urology: state of the art. Arch Esp Urol (2011) 1.38
Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer. Int J Cancer (2004) 1.34
Small cell carcinoma of the bladder. BJU Int (2004) 1.33
Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J Urol (2008) 1.33
Limitations of biopsy Gleason grade: implications for counseling patients with biopsy Gleason score 6 prostate cancer. J Urol (2004) 1.27
Lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. BJU Int (2011) 1.23
Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer. Cancer Res (2003) 1.22
Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol (2003) 1.21
Prostate specific antigen recurrence rates are low after radical retropubic prostatectomy and positive margins. J Urol (2006) 1.18
Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence. Int J Cancer (2006) 1.17
Long-term survival in patients undergoing radical nephrectomy and inferior vena cava thrombectomy: single-center experience. Eur Urol (2009) 1.15
Secondary cancer after radiotherapy for prostate cancer: should we be more aware of the risk? Eur Urol (2007) 1.15
Sexual, psychological and dyadic qualities of the prostate cancer 'couple'. BJU Int (2005) 1.14
Grade 4 cystocele repair using four-defect repair and porcine xenograft acellular matrix (Pelvicol): outcome measures using SEAPI. Urology (2004) 1.14
Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence. Clin Cancer Res (2008) 1.13
Factors that influence patient enrollment in active surveillance for low-risk prostate cancer. Urology (2011) 1.11
Risk of positive margins and biochemical recurrence in relation to nerve-sparing radical prostatectomy. J Clin Oncol (2002) 1.10
Cystoprostatectomy and orthotopic ileal neobladder reconstruction for management of bacille Calmette Guérin-induced bladder contractures. Urology (2005) 1.06
Regulation of hyaluronidase activity by alternative mRNA splicing. J Biol Chem (2002) 1.05
A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol (2013) 1.05
Liver transplantation techniques for the surgical management of renal cell carcinoma with tumor thrombus in the inferior vena cava: step-by-step description. Eur Urol (2010) 1.04
Positive surgical margins after radical retropubic prostatectomy: the influence of site and number on progression. J Urol (2002) 1.03
Polymorphisms in the DNA methyltransferase 3b gene and prostate cancer risk. Oncol Rep (2005) 1.02
Bladder cancer after radiotherapy for prostate cancer: detailed analysis of pathological features and outcome after radical cystectomy. J Urol (2007) 1.02
Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests. Cancer (2002) 1.01
Current bladder cancer tests: unnecessary or beneficial? Crit Rev Oncol Hematol (2003) 0.99
The diagnosis and staging of bladder cancer: from RBCs to TURs. Urology (2006) 0.98
Factors affecting erectile function after radical retropubic prostatectomy: results from 1620 consecutive patients. BJU Int (2008) 0.98
It is time to abandon the "superficial" in bladder cancer. Eur Urol (2007) 0.98
Trends in Gleason score: concordance between biopsy and prostatectomy over 15 years. Urology (2008) 0.96
HAS1 expression in bladder cancer and its relation to urinary HA test. Int J Cancer (2007) 0.95
Renal cell carcinoma with tumor thrombus extending above diaphragm: avoiding cardiopulmonary bypass. Urology (2005) 0.95
Chemokine and chemokine receptor expression in kidney tumors: molecular profiling of histological subtypes and association with metastasis. J Urol (2012) 0.94
C-X-C chemokine receptor 7: a functionally associated molecular marker for bladder cancer. Cancer (2012) 0.93
Intraoperative cell salvage during radical cystectomy does not affect long-term survival. Urology (2007) 0.93
Prostate sampling by 12-core biopsy: comparison of the biopsy results with tumor location in prostatectomy specimens. Urology (2011) 0.92
Intraoperative cell salvage during radical prostatectomy is not associated with greater biochemical recurrence rate. Urology (2005) 0.91
Prostatic involvement by urothelial carcinoma of the bladder: clinicopathological features and outcome after radical cystectomy. BJU Int (2007) 0.91
Epigenetic regulation of HYAL-1 hyaluronidase expression. identification of HYAL-1 promoter. J Biol Chem (2008) 0.91